About Abterra Biosciences
Abterra Biosciences is a Healthcare company based in San Diego (United States) founded in 2009. Antibody sequencing and analysis are enabled by advanced technologies. Abterra Biosciences has raised $200 thousand across 10 funding rounds from investors including HHS and Seattle Angel Conference. Abterra Biosciences offers products and services including REPTOR, ALICANTO, VALENS, and GRIFFIN. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its competitors include Nimbus Therapeutics, EvolutionaryScale and Evozyne; 3 of its 3 listed competitors have raised funding.
Company details
Abterra Biosciences was founded in 2009 and is based in San Diego, United States. Operations in the biotechnology sector focus on a platform that employs next-generation sequencing, mass spectrometry, and machine learning. Antibody responses to infectious diseases and cancer are mapped, therapeutic antibodies are identified, and services include antibody-protein sequence analysis, monoclonal antibody discovery, and B-cell sequencing.
- Headquarters San Diego, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website abterrabio.com
- Social LinkedIn X Facebook
- Total Equity Funding$200K (USD)
in 10 rounds
- Latest Funding Round$1.1M (USD), Grant
Jul 2021
- InvestorsHHS
& 1 more
Products & Services of Abterra Biosciences
Abterra Biosciences offers a comprehensive portfolio of products and services, including REPTOR, ALICANTO, VALENS, and GRIFFIN.
Next-generation sequencing for hybridoma and B cell analysis
Platform for rabbit and human antibody identification services
Service for antibody protein sequence confirmation and analysis
Tool for polyclonal antibody sequencing and recombinant production
Funding Insights of Abterra Biosciences
Abterra Biosciences has successfully raised a total of $200K across 10 strategic funding rounds. The most recent funding activity was a Grant round of $1.1 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $200,000
- Total Rounds 10
- Last Round Grant — $1.1M
- First Round $480,109
(May 2012)
- Investors Count 2
All 10 funding rounds of Abterra Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | $1.1M | Grant | – | – | |
| May 2021 | $200,000 | Seed | – | – | |
| Mar 2021 | $1.55M | Grant | – | – | |
| Feb 2021 | $244,049 | Grant | – | – | |
| Apr 2020 | $1.07M | Grant | – | – | |
| Aug 2018 | $170,108 | Grant | – | – | |
| Feb 2018 | $1.57M | Grant | – | – | |
| Feb 2017 | $886,819 | Grant | – | – | |
| Jun 2012 | $1.13M | Grant | – | – | |
| May 2012 | $480,109 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Abterra Biosciences
Abterra Biosciences has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS and Seattle Angel Conference.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A program focused on angel investing and startup funding is offered. | seattleangelconference.com | Seattle, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Abterra Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Abterra Biosciences
8 people are tracked at Abterra Biosciences (3 in leadership, 5 in team).
| Name | Role | Group |
|---|---|---|
Thiago Lima | Director of Operations | Leadership |
Anand Patel | CTO | Leadership |
Natalie Castellana | CEO | Leadership |
Stefano Bonissone | CSO | Team |
Richard Carson | Bioanalytical Scientist III | Team |
Brinley Moorman | Research Associate II | Team |
Mar De La Cruz | Research Associate II | Team |
Emily Ramsey | Accountant | Team |
Complete people profiles for Abterra Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Abterra Biosciences
3 dated milestones of Abterra Biosciences across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Abterra Biosciences is founded.
- Funding First funding round of $480K.
- Funding Latest funding round, Grant, of $1.1M.
Competitors of Abterra Biosciences
Abterra Biosciences has 3 listed competitors in our database, 3 of them funded. They include Nimbus Therapeutics, EvolutionaryScale and Evozyne.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| evolutionaryscale.ai | 2023 | New York, United States | $142M | Provider of an AI models for protein design | ||
| evozyne.com | 2020 | Chicago, United States | $144.37M | Developer of proteins using protein engineering technology |
Detailed competitors of Abterra Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Abterra Biosciences
The website of Abterra Biosciences (abterrabio.com) receives about 2.3K visits a month.
- Monthly visits2.3K
▲ 24.2% vs previous month
Websites whose visitors overlap most with Abterra Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| alfascientific.com | 100% | #8,547,751 | View details | ||
medsalesinstitute.com | medsalesinstitute.com | 98% | #8,826,142 | – | |
tiger-aesthetics.com | tiger-aesthetics.com | 98% | #3,583,261 | – | |
| carihealth.com | 98% | View details | |||
| truvianhealth.com | 98% | 4.2K | #4,492,336 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Abterra Biosciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Abterra Biosciences (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Abterra Biosciences
Abterra Biosciences was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Abterra Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Abterra Biosciences is a funded company, having raised a total of $200K across 10 funding rounds to date. The company's 1st funding round was a Grant of $480.11K, raised on May 2012.
Abterra Biosciences was founded in 2009 and is based in San Diego, United States. Operations in the biotechnology sector focus on a platform that employs next-generation sequencing, mass spectrometry, and machine learning. Antibody responses to infectious diseases and cancer are mapped, therapeutic antibodies are identified, and services include antibody-protein sequence analysis, monoclonal antibody discovery, and B-cell sequencing.
Abterra Biosciences's top competitors include Nimbus Therapeutics, EvolutionaryScale and Evozyne.
Abterra Biosciences offers REPTOR, ALICANTO, VALENS, and GRIFFIN.
Abterra Biosciences has 2 investors. Key investors include HHS, and Seattle Angel Conference.